Murray, Frank & Sailer LLP Investigates Breaches Of Fiduciary Duty Regarding Acquisition Of TomoTherapy Incorporated By Accuray Incorporated

Murray, Frank & Sailer LLP is investigating claims of breach of fiduciary duty by certain members of the board of directors of TomoTherapy Incorporated (NASDAQ: TOMO) ("TomoTherapy” or the "Company”) in relation to the acquisition of the Company by Accuray Incorporated ("Accuray”).

On March 7, 2011, TomoTherapy and Accuray announced that Accuray will acquire TomoTherapy pursuant to a transaction under which TomoTherapy stockholders will receive $3.15 in cash and 0.1648 shares of Accuray stock, or approximately $4.80, for each share of TomoTherapy common stock, an aggregate value of approximately $277 million. The amount represents a premium of approximately 31% over the closing price of the stock on March 4, 2011.

The investigation concerns whether certain members of the board of directors breached their fiduciary duty in connection with their efforts to sell TomoTherapy to Accuray at an inadequate price through an unfair process which significantly undervalues the Company.

If you are a current investor in TomoTherapy, who purchased TOMO shares before March 7, 2011, and you wish to discuss this investigation or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Bridget Hamill at (800) 497-8076 or (212) 682-1818, or by email at investigations@murrayfrank.com.